PTGX

Protagonist Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · protagonist-inc.com

$99.21

Mkt Cap $6.3B

52w Low $41.28 87.0% of range 52w High $107.84

50d MA $98.72 200d MA $79.97

P/E (TTM) -48.0x

EV/EBITDA -42.4x

P/B 10.2x

Debt/Equity 0.0x

ROE -21.2%

P/FCF 99.0x

RSI (14) —

ATR (14) —

Beta 2.11

50d MA $98.72

200d MA $79.97

Avg Volume 773.8K

About

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	-0.53	-0.69	-30.2%	87.10	+0.5%	+1.5%	+5.7%	+8.2%	+4.8%	+8.9%	—
Nov 6, 2025	AMC	-0.59	-0.62	-5.1%	79.78	+0.4%	-0.3%	+4.3%	+7.2%	+6.4%	+4.3%	—
Aug 6, 2025	AMC	-0.53	-0.55	-3.8%	53.87	+0.5%	-5.4%	-5.2%	-0.2%	+1.2%	+5.3%	—
May 6, 2025	AMC	-0.50	-0.19	+62.0%	42.01	-0.6%	+2.6%	+4.5%	+2.3%	+7.8%	+5.4%	—
Feb 21, 2025	AMC	0.06	1.98	+3200.0%	38.75	+0.0%	-7.1%	-9.4%	-6.7%	-6.2%	-3.0%	—
Nov 7, 2024	AMC	-0.59	-0.54	+8.5%	47.61	+2.6%	-2.9%	-2.3%	-9.3%	-10.4%	-13.8%	—
Aug 6, 2024	AMC	-0.50	-0.50	+0.0%	36.21	+1.2%	-1.2%	+2.7%	+6.9%	+12.1%	+11.3%	—
May 7, 2024	AMC	1.19	3.26	+173.9%	25.79	+5.0%	+5.1%	+9.6%	+9.5%	+13.7%	+14.8%	—
Feb 27, 2024	AMC	0.03	0.44	+1425.3%	29.59	+1.4%	+2.8%	+2.7%	+8.7%	+7.0%	+4.6%	—
Nov 2, 2023	AMC	-0.68	-0.58	+14.7%	15.41	+2.3%	+8.0%	+5.7%	+6.9%	+3.6%	-2.4%	—
Aug 3, 2023	AMC	-0.65	-0.68	-4.6%	18.57	-0.2%	+3.3%	+1.9%	-2.0%	-1.8%	+1.2%	—
May 4, 2023	AMC	-0.69	-0.67	+2.9%	23.60	+4.8%	+5.1%	+5.6%	+7.0%	+6.0%	+4.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 15	Truist	Maintains	Buy → Buy	—	$104.72	$105.96	+1.2%	+0.7%	-0.9%	+1.2%	+0.7%	+1.1%
Apr 7	Clear Street	Maintains	Buy → Buy	—	$102.89	$103.43	+0.5%	+0.8%	-0.8%	+1.2%	-4.0%	-5.2%
Mar 19	Barclays	Maintains	Overweight → Overweight	—	$97.09	$98.45	+1.4%	+4.7%	+1.8%	+1.5%	+3.4%	+7.4%
Mar 19	Leerink Partners	Maintains	Outperform → Outperform	—	$97.09	$98.45	+1.4%	+4.7%	+1.8%	+1.5%	+3.4%	+7.4%
Mar 19	JP Morgan	Maintains	Overweight → Overweight	—	$97.09	$98.45	+1.4%	+4.7%	+1.8%	+1.5%	+3.4%	+7.4%
Mar 19	Citigroup	Maintains	Buy → Buy	—	$97.09	$98.45	+1.4%	+4.7%	+1.8%	+1.5%	+3.4%	+7.4%
Mar 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$94.24	$92.56	-1.8%	-3.1%	+0.6%	-3.0%	-2.3%	+2.6%
Feb 26	Barclays	Maintains	Overweight → Overweight	—	$87.10	$87.50	+0.5%	+1.5%	+5.7%	+8.2%	+4.8%	+8.9%
Feb 26	TD Cowen	Maintains	Buy → Buy	—	$87.10	$87.50	+0.5%	+1.5%	+5.7%	+8.2%	+4.8%	+8.9%
Feb 26	Citizens	Maintains	Market Outperform → Market Outperform	—	$87.10	$87.50	+0.5%	+1.5%	+5.7%	+8.2%	+4.8%	+8.9%
Feb 2	Jefferies	Maintains	Buy → Buy	—	$81.80	$81.80	+0.0%	+1.5%	+4.6%	+1.8%	-1.4%	+3.3%
Jan 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$79.73	$79.77	+0.1%	+2.6%	+4.2%	+7.3%	+4.5%	+1.2%
Jan 5	Truist	Maintains	Buy → Buy	—	$87.18	$87.53	+0.4%	-3.4%	-5.6%	-5.6%	-8.0%	-8.0%
Dec 17	Barclays	Maintains	Overweight → Overweight	—	$91.54	$91.41	-0.1%	-2.4%	-6.3%	-6.0%	-4.5%	-3.1%
Dec 8	Citigroup	Maintains	Buy → Buy	—	$89.65	$90.94	+1.4%	+0.7%	-1.2%	+1.9%	+2.9%	+6.4%
Nov 10	Citigroup	Maintains	Buy → Buy	—	$79.54	$80.58	+1.3%	+4.6%	+7.6%	+6.7%	+4.7%	+6.4%
Nov 7	Barclays	Maintains	Overweight → Overweight	—	$79.78	$80.12	+0.4%	-0.3%	+4.3%	+7.2%	+6.4%	+4.3%
Nov 7	JP Morgan	Maintains	Overweight → Overweight	—	$79.78	$80.12	+0.4%	-0.3%	+4.3%	+7.2%	+6.4%	+4.3%
Nov 7	Citizens	Maintains	Market Outperform → Market Outperform	—	$79.78	$80.12	+0.4%	-0.3%	+4.3%	+7.2%	+6.4%	+4.3%
Oct 28	Wedbush	Maintains	Outperform → Outperform	—	$75.25	$75.06	-0.3%	+4.3%	+1.9%	+3.5%	+4.5%	+0.9%
Oct 28	Truist	Maintains	Buy → Buy	—	$75.25	$75.06	-0.3%	+4.3%	+1.9%	+3.5%	+4.5%	+0.9%
Oct 28	BTIG	Maintains	Buy → Buy	—	$75.25	$75.06	-0.3%	+4.3%	+1.9%	+3.5%	+4.5%	+0.9%
Oct 17	Citigroup	Maintains	Buy → Buy	—	$75.73	$75.60	-0.2%	+2.3%	+1.3%	-1.0%	-2.9%	-2.3%
Oct 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$65.47	$65.28	-0.3%	-0.3%	+2.4%	+32.9%	+20.9%	+17.5%
Sep 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$58.59	$60.05	+2.5%	+1.1%	+6.1%	+6.2%	+10.1%	+11.0%
Aug 7	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$53.87	$54.12	+0.5%	-5.4%	-5.2%	-0.2%	+1.2%	+5.3%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.15	$49.91	-0.5%	+1.8%	+2.8%	+7.3%	+8.4%	+11.0%
May 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$44.49	$44.45	-0.1%	+2.4%	+4.8%	+3.0%	+3.2%	+2.6%
Apr 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.57	$41.44	-2.7%	-3.9%	+0.1%	+5.8%	+10.3%	+7.6%
Mar 28	Wedbush	Maintains	Outperform → Outperform	—	$49.44	$49.47	+0.1%	-1.1%	-2.2%	-5.2%	-2.5%	-5.9%
Mar 11	Truist	Maintains	Buy → Buy	—	$55.95	$55.90	-0.1%	+6.8%	+3.0%	-1.9%	-2.1%	-5.3%
Mar 11	BMO Capital	Maintains	Outperform → Outperform	—	$55.95	$55.90	-0.1%	+6.8%	+3.0%	-1.9%	-2.1%	-5.3%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$55.95	$55.90	-0.1%	+6.8%	+3.0%	-1.9%	-2.1%	-5.3%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.35	$50.08	+30.6%	+45.9%	+55.8%	+50.3%	+43.2%	+42.8%
Mar 10	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$38.35	$50.08	+30.6%	+45.9%	+55.8%	+50.3%	+43.2%	+42.8%
Mar 4	JP Morgan	Maintains	Overweight → Overweight	—	$38.50	$38.24	-0.7%	+0.4%	-0.1%	+1.4%	-0.4%	+45.3%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.59	$40.81	+8.6%	+2.4%	+2.8%	+2.3%	+3.9%	+2.0%
Feb 24	Goldman Sachs	Maintains	Neutral → Neutral	—	$38.75	$38.75	+0.0%	-7.1%	-9.4%	-6.7%	-6.2%	-3.0%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.75	$38.75	+0.0%	-7.1%	-9.4%	-6.7%	-6.2%	-3.0%
Feb 7	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$37.75	$37.81	+0.2%	+3.0%	+0.6%	-2.0%	-0.9%	+2.5%
Feb 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.75	$37.81	+0.2%	+3.0%	+0.6%	-2.0%	-0.9%	+2.5%
Feb 4	JP Morgan	Maintains	Overweight → Overweight	—	$37.20	$37.55	+0.9%	+1.0%	+3.5%	+1.5%	+4.5%	+2.1%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.50	$40.70	+0.5%	+2.7%	+1.2%	-0.3%	+1.4%	+2.4%
Nov 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.65	$43.30	+4.0%	+11.5%	+9.3%	+7.6%	+7.9%	+5.2%
Nov 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.39	$38.27	-5.2%	-4.3%	+0.6%	+3.1%	+15.0%	+12.7%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$46.23	$46.90	+1.4%	+0.6%	-6.6%	-7.7%	-11.2%	-11.1%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$44.79	$45.25	+1.0%	+1.9%	+5.0%	+3.1%	+0.3%	-0.0%
Aug 7	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$36.21	$36.63	+1.2%	-1.2%	+2.7%	+6.9%	+12.1%	+11.3%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$36.21	$36.63	+1.2%	-1.2%	+2.7%	+6.9%	+12.1%	+11.3%
Jul 25	JP Morgan	Maintains	Overweight → Overweight	—	$41.89	$41.62	-0.6%	-0.8%	-3.8%	-7.4%	-10.1%	-10.6%

Recent Filings

8-K

Protagonist Therapeutics, Inc -- 8-K Filing

Protagonist Therapeutics expects regulatory decisions on ICOTYDE in 2026 with potential launch this year, while advancing PN-881 through Phase 1 and expanding its preclinical pipeline with new wholly-owned candidates.

Feb 25

Data updated apr 26, 2026 9:08pm · Source: massive.com